Amneal Pharmaceuticals (STU:2DT) Interest Expense: €-204 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2DT Amneal Pharmaceuticals Inc STU:2DT
63 GF Score
Price €15.00
GF Value €6.62
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Amneal Pharmaceuticals Interest Expense?

Amneal Pharmaceuticals STU:2DT +1.35% 63 Interest Expense is €-204 Mil as of Mar. 2026. GuruFocus rates STU:2DT with a GF Score™ of 63/100 and a GF Value™ of €6.62 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Amneal Pharmaceuticals's interest expense for the three months ended in Mar. 2026 was € -46 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-204 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Amneal Pharmaceuticals's Operating Income for the three months ended in Mar. 2026 was € 128 Mil. Amneal Pharmaceuticals's Interest Expense for the three months ended in Mar. 2026 was € -46 Mil. Amneal Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2026 was 2.78. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Amneal Pharmaceuticals  (STU:2DT) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Amneal Pharmaceuticals's Interest Expense for the three months ended in Mar. 2026 was €-46 Mil. Its Operating Income for the three months ended in Mar. 2026 was €128 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €2,314 Mil.

Amneal Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Interest Coverage=-1* Operating Income (Q: Mar. 2026 )/Interest Expense (Q: Mar. 2026 )
=-1*128.253/-46.157
=2.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Amneal Pharmaceuticals Interest Expense Historical Data

* Premium members only.

The historical data trend for Amneal Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amneal Pharmaceuticals Interest Expense Chart

Amneal Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -120.65 -149.51 -193.15 -246.96 -205.89

Amneal Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -52.67 -56.44 -53.52 -48.03 -46.16
STU:2DT
63GF Score
Amneal Pharmaceuticals Inc STU:2DT
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amneal Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-204 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-204 Mil mean?
Amneal Pharmaceuticals (STU:2DT) has a Interest Expense of €-204 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Amneal Pharmaceuticals and its competitors.
Is Amneal Pharmaceuticals' Interest Expense too high?
Amneal Pharmaceuticals' current Interest Expense is €-204 Mil. Overall, Amneal Pharmaceuticals has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' Interest Expense compare to INDV and KNSA?
Amneal Pharmaceuticals' Interest Expense of €-204 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Amneal Pharmaceuticals and its competitors. Amneal Pharmaceuticals's current Interest Expense is €-204 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (STU:2DT) is currently considered Significantly Overvalued. The stock's GF Value™ is €6.62, compared to a current price of €15.00 — trading 126.6% above its estimated fair value. The current Interest Expense is €-204 Mil. Amneal Pharmaceuticals' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Amneal Pharmaceuticals (STU:2DT), the current Interest Expense is €-204 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amneal Pharmaceuticals (STU:2DT) Overvalued in 2026?

Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued. The current stock price of €15.00 is trading 126.6% above its estimated GF Value™ of €6.62. GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:2DT:

  • Interest Expense: €-204 Mil
  • GF Value™: €6.62 vs. price of €15.00 (126.6% above fair value)
  • GF Score™: 63/100 with 6 warning signs

No single metric tells the full story. See the STU:2DT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amneal Pharmaceuticals Business Description

Other Exchanges AMRX:USA
Address 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
63GF Score

Get the complete analysis for STU:2DT

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.00
Price
€6.62
GF Value